These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 27207455)

  • 1. Development of a primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma during treatment of multiple sclerosis with fingolimod.
    Papathemeli D; Gräfe R; Hildebrandt U; Zettl UK; Ulrich J
    Mult Scler; 2016 Dec; 22(14):1888-1890. PubMed ID: 27207455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous anaplastic large cell lymphoma in a multiple sclerosis patient receiving Fingolimod.
    Manouchehri N; Mirmosayyeb O; Badihian S; Shaygannejad V
    Mult Scler Relat Disord; 2018 Jan; 19():121-123. PubMed ID: 29195114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary cutaneous CD30
    Connolly A; Grandi V; Stefanato CM; Palmer R; Weir A; Whittaker S
    Br J Dermatol; 2018 Dec; 179(6):1400-1401. PubMed ID: 30007065
    [No Abstract]   [Full Text] [Related]  

  • 4. A Case of cutaneous large B-cell lymphoma during treatment of multiple sclerosis with fingolimod.
    Stitt DW; Boes CJ; Flanagan EP; Howard MT; Colgan JP
    Mult Scler Relat Disord; 2018 Jan; 19():115-117. PubMed ID: 29190574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Primary cutaneous CD30+ T-cell lymphoproliferation during treatment with fingolimod: Case report and literature review].
    Cesbron E; Monfort JB; Giannesini C; Duriez P; Moguelet P; Senet P; Francès C; Barbaud A; Chasset F
    Ann Dermatol Venereol; 2018; 145(6-7):433-438. PubMed ID: 29673751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphomatoid papulosis: A cutaneous lymphoproliferative disorder in a patient on fingolimod for multiple sclerosis.
    Samaraweera AP; Cohen SN; Akay EM; Evangelou N
    Mult Scler; 2016 Jan; 22(1):122-4. PubMed ID: 26219664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary mediastinal large B-cell lymphoma in a patient on Fingolimod for relapsing-remitting multiple sclerosis.
    Chacko JA; Strati P; Stout PW; Archer RL; Baltz BP; Chacko JG
    Mult Scler Relat Disord; 2021 Apr; 49():102776. PubMed ID: 33508568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycosis fungoides - A cutaneous lymphoproliferative disorder in a patient treated with fingolimod for multiple sclerosis.
    Nitsan Z; Kucuk N; Appel S; Tichmanovich N; Osherov M; Milo R
    J Clin Neurosci; 2018 Feb; 48():102-103. PubMed ID: 29108666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glatiramer acetate-associated, CD30+, primary, cutaneous, anaplastic large-cell lymphoma.
    Madray MM; Greene JF; Butler DF
    Arch Neurol; 2008 Oct; 65(10):1378-9. PubMed ID: 18852356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fingolimod (Gilenya) and melanoma.
    Robinson CL; Guo M
    BMJ Case Rep; 2016 Dec; 2016():. PubMed ID: 28003234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous cryptococcosis in a patient taking fingolimod for multiple sclerosis: Here come the opportunistic infections?
    Carpenter AF; Goodwin SJ; Bornstein PF; Larson AJ; Markus CK
    Mult Scler; 2017 Feb; 23(2):297-299. PubMed ID: 28165320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
    Hatcher SE; Waubant E; Nourbakhsh B; Crabtree-Hartman E; Graves JS
    JAMA Neurol; 2016 Jul; 73(7):790-4. PubMed ID: 27135594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retinal hemorrhages following fingolimod treatment for multiple sclerosis; a case report.
    Ueda N; Saida K
    BMC Ophthalmol; 2015 Oct; 15():135. PubMed ID: 26481728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe Exacerbation of Multiple Sclerosis Following Withdrawal of Fingolimod.
    Fragoso YD; Adoni T; Gomes S; Goncalves MVM; Parolin LF; Rosa G; Ruocco HH
    Clin Drug Investig; 2019 Sep; 39(9):909-913. PubMed ID: 31152369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary central nervous system lymphoma in a patient with multiple sclerosis using fingolimod.
    Morillos MB; de Aguiar PHP; Franceschini PR; Duarte JÁ; Piccini CD; Finkelsztejn A
    Neurol Sci; 2023 Jan; 44(1):361-363. PubMed ID: 36031684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease reactivation following fingolimod withdrawal in multiple sclerosis: Two case reports.
    Forci B; Mariottini A; Mechi C; Massacesi L; Repice A
    Mult Scler Relat Disord; 2017 Jul; 15():24-26. PubMed ID: 28641768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe rebound after withdrawal of fingolimod treatment in patients with multiple sclerosis.
    Gündüz T; Kürtüncü M; Eraksoy M
    Mult Scler Relat Disord; 2017 Jan; 11():1-3. PubMed ID: 28104247
    [No Abstract]   [Full Text] [Related]  

  • 18. Listeria monocytogenes rhombencephalitis in a patient with multiple sclerosis during fingolimod therapy.
    Tecellioglu M; Kamisli O; Kamisli S; Erdogmus UA; Özcan C
    Mult Scler Relat Disord; 2019 Jan; 27():409-411. PubMed ID: 30530070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurodevelopmental retardation in a baby born to a multiple sclerosis patient being treated with fingolimod.
    Cheraghmakani H; Nasehi MM; Baghbanian SM
    Mult Scler Relat Disord; 2019 Aug; 33():116-120. PubMed ID: 31185372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visceral leishmaniasis infection in a fingolimod-treated multiple sclerosis patient.
    Artemiadis AK; Nikolaou G; Kolokythopoulos D; Tegos N; Terentiou A; Triantafyllou N; Papanastasiou I
    Mult Scler; 2015 May; 21(6):795-6. PubMed ID: 25432949
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.